Optum guides providers through important upcoming formulary updates
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 24, 2017 – The FDA approved a new Warning to the Keppra/Keppra XR (levetiracetam) drug labels regarding anaphylaxis and angioedema.
Download PDF
Return to publications
